logotype
logotype

Category: News

novo
December 26, 2024
by info@virtueinsight.comNews

Novo Holdings completes Catalent acquisition for $16.5bn

Novo Holdings, a global investment firm focused on life sciences, has completed its previously announced acquisition of Catalent. Under private ownership, Catalent benefits from Novo Holdings’ significant resources, and is well-positioned to deliver unparalleled outcomes for...
read more
abbvie
December 26, 2024
by info@virtueinsight.comNews

AbbVie buys Nimble Therapeutics for $200M

AbbVie is paying $200 million to snap up Nimble Therapeutics, a Roche spinout working to develop oral peptide treatments in the autoimmune space. As part of the acquisition, the North Chicago-based Big Pharma will also dole out undisclosed interim payments. Shareholders of the...
read more
ge
December 26, 2024
by info@virtueinsight.comNews

GE HealthCare fully acquires Japanese pharma company

GE HealthCare has acquired full ownership of a leading radiopharmaceutical firm Nihon Medi-Physics, that generated $183 million in revenue last year.  NMP’s product portfolio includes GE HealthCare radiopharmaceuticals delivered across neurology, cardiology and oncology. Among them...
read more
December 26, 2024
by info@virtueinsight.comNews

AbbVie to Acquire Aliada Therapeutics

AbbVie and Aliada Therapeutics had announced a definitive agreement under which AbbVie will acquire Aliada, a biotechnology company advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases....
read more
November 9, 2024
by info@virtueinsight.comNews

Modifi Biosciences Acquired by Merck

  Modifi Biosciences, a leader in the development of direct DNA modification enabled cancer therapeutics, had announced that the company has been acquired by Merck, known as MSD outside of the United States and Canada. “In founding Modifi Biosciences, we sought to radically change...
read more
November 9, 2024
by info@virtueinsight.comNews

Lundbeck to buy Longboard Pharmaceuticals for $2.6bn

Lundbeck has entered an agreement to acquire Longboard Pharmaceuticals for an equity value of $2.6 billion, aiming to strengthen its portfolio in the field of neuro-rare conditions. The transaction holds a net worth of $2.5 billion, assessed on a fully diluted basis. Lundbeck’s...
read more
November 9, 2024
by info@virtueinsight.comNews

Agilent Completes Acquisition of BIOVECTRA

Agilent Technologies had announced the company has completed its acquisition of BIOVECTRA, a Canada-based contract development and manufacturing organization (CDMO) that specializes in biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted...
read more
August 19, 2024
by info@virtueinsight.comNews

Mankind Pharma acquires Bharat Serums and Vaccines for $1.6bn

  Mankind Pharma has announced a definitive agreement for the acquisition of a 100% stake in Bharat Serums and Vaccines (BSV) from private equity investor Advent International in a Rs136.3bn ($1.6bn) deal. The move bolsters Mankind Pharma’s position in the Indian women’s...
read more
August 19, 2024
by info@virtueinsight.comNews

Eli Lilly inaugurates R&D facility in Boston

Eli Lilly and Company has opened the Lilly Seaport Innovation Center (LSC), a research and development (R&D) hub in the Seaport district of Boston, US. The centre is set to progress the company’s work on RNA and DNA-based therapies and discover new drug targets for...
read more
August 19, 2024
by info@virtueinsight.comNews

Boehringer Ingelheim acquires Nerio Therapeutics for $1.3bn

  Boehringer Ingelheim has acquired drug discovery and development company Nerio Therapeutics in a $1.3bn deal. Nerio’s small molecules inhibit the protein tyrosine phosphatases N1 and N2 (PTPN1 and PTPN2), which act as immune checkpoints. Through this mechanism, PTPN1/2...
read more